Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Warns Novartis, Shire On Misbranding

May 09 2008

• By Emily Hayes

Related Content

Fosrenol Approved In Higher Dose Formulation

Nov 28 2005

Novartis Trileptal Label Adds Warning On Dermatological Reactions

Apr 19 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window